Table 5.
Average pharmacokinetic parameters (mean ± standard error (SE)) after administration of MK-A formulations (15 mpk) to pentagastrin-pretreated male Beagle dogs (n = 3 or 6).
| Formulation | Dose (mpk) | AUC0–24 h (µM × h) | Cmax (µM) | Tmax (h) | AUC Ratio (Versus DFC) |
|---|---|---|---|---|---|
| HME capsules (n = 6) | 15 | 12.4 ± 2.65 | 2.22 ± 0.42 | 2.0 (2.0–4.0) * | 1.33 |
| SDD capsules (n = 3) | 15 | 7.59 ± 1.44 | 1.19 ± 0.00 | 4.0 (4.0–4.0) * | 0.81 |
| SDD suspension (n = 6) | 15 | 14.7 ± 2.13 | 2.62 ± 0.19 | 2.0 (2.0–4.0) * | 1.58 |
| Solution (n = 3) | 15 | 22.4 ± 3.41 | 3.73 ± 0.38 | 2.0 (2.0–2.0) * | 2.40 |
| DFC (Benchmark, n = 6) | 15 | 9.35 ± 1.34 | 1.82 ± 0.34 | 2.0 (1.0–2.0) * | 1.00 |
* For Tmax, the median value is provided along with the range in parenthesis; AUC: area under curve; DFC: dry-filled capsule.